grant
Anti-ceramide immunotherapy for diabetic retinopathy
Organization UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTRLocation OKLAHOMA CITY, UNITED STATESPosted 1 Aug 2019Deadline 30 Apr 2030
NIHUS FederalResearch GrantFY2026(TNF)-αAdult-Onset Diabetes MellitusAffectAnimal ModelAnimal Models and Related StudiesAnti-InflammatoriesAnti-Inflammatory AgentsAnti-VEGFAnti-VEGF Humanized Monoclonal AntibodyAnti-VEGF RhuMAbAnti-inflammatoryAntibodiesApoptosisApoptosis PathwayApoptoticAreaBeta Proprotein Interleukin 1Bilayer FluidityBindingBlood CellsBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood VesselsBlood monocyteBody TissuesBone MarrowBone Marrow Blood-Deriving CellBone Marrow Blood-Forming CellBone Marrow CellsBone Marrow Reticuloendothelial SystemBrittle Diabetes MellitusC(16)-ceramideC16-0(palmitoyl)ceramideC16-ceramideCD34CD34 geneCachectinCardiovascular DiseasesCell BodyCell Communication and SignalingCell DeathCell Membrane LipidsCell SignalingCell membraneCell surfaceCellsCellular injuryCeramidesChronicCirculationClinical TrialsComplicationCytoplasmic MembraneCytotoxic TRAIL Receptor-2DR5DR5 proteinDataDeath Receptor 5DevelopmentDiabetes MellitusDiabetic RetinopathyDiabetic mouseDiseaseDisorderDrug TargetingDrug TherapyDysfunctionDyslipidemiasElementsEndothelial CellsEnzyme GeneEnzymesExhibitsFas-Like Protein PrecursorFunctional disorderFundingGenerationsHPCA1HematopoiesisHematopoieticHematopoietic Cellular Control MechanismsHumanHydrolysisIDDMIL-1 betaIL-1 βIL-1-bIL-1βIL1-BetaIL1-βIL1B ProteinIL1F2IL1βImmune mediated therapyImmunologically Directed TherapyImmunotherapyIn VitroIndividualInflammatoryInjuryInsulin-Dependent Diabetes MellitusInterleukin 1betaInterleukin-1 betaInterleukin-1βIntracellular Communication and SignalingJuvenile-Onset Diabetes MellitusKILLER/DR5Ketosis-Prone Diabetes MellitusKetosis-Resistant Diabetes MellitusLipidsMacrophage-Derived TNFMarrow NeutrophilMarrow monocyteMaturity-Onset Diabetes MellitusMediatingMembrane FluidityMembrane LipidsMicroRNAsMoAb VEGFModelingModern ManMolecular InteractionMonoclonal Antibody Anti-VEGFMonocyte-Derived TNFMorphologyMyelogenousMyeloidN-palmitoylsphingosineNFA(C16)CERNIDDMNeuropathyNeutrophilic GranulocyteNeutrophilic LeukocyteNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusOrganOutcomePathogenesisPathologicPathologyPatientsPerfusionPeripheral Blood CellPharmacological TreatmentPharmacotherapyPhenocopyPhysiologicPhysiologicalPhysiopathologyPlasma MembranePolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPopulationPreinterleukin 1 BetaProductionProgrammed Cell DeathProtein DynamicsPublishingRecombinant Humanized Anti-VEGF Monoclonal AntibodyRecombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth FactorRetinaRetinal Blood VesselsRetinal VesselsRhuMAb VEGFRodentRodent ModelRodentiaRodents MammalsRoleSeriesSeveritiesShort interfering RNASignal InductionSignal TransductionSignal Transduction SystemsSignalingSlow-Onset Diabetes MellitusSmall Interfering RNASphingomyelinsStable Diabetes MellitusSudden-Onset Diabetes MellitusT1 DMT1 diabetesT1DT1DMT2 DMT2DT2DMTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFRSF10BTNFRSF10B geneTNFαTRAIL Receptor 2TRAIL-R2TRAILR2TRICK2TRICK2ATRICK2BTRICKBTestingTherapeuticTissuesTumor Necrosis FactorTumor Necrosis Factor Receptor-Like Protein ZTNFR9Tumor Necrosis Factor-alphaType 1 Diabetes MellitusType 1 diabetesType 2 Diabetes MellitusType 2 diabetesType I Diabetes MellitusType II Diabetes MellitusType II diabetesVasa NervorumZTNFR9acid sphingomyelinaseadult onset diabetesassess effectivenessbevacizumabbiological signal transductionblood cell formationcardiovascular disordercell damagecell injurycellular damagedamage to cellsdetermine effectivenessdevelopmentaldiabetesdiabetes mouse modeldiabeticdiabetic patientdrug interventiondrug treatmenteffectiveness assessmenteffectiveness evaluationendothelial dysfunctionevaluate effectivenessexamine effectivenesshemopoieticimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyin vivoinjuriesinjury to cellsinsulin dependent diabetesinsulin dependent type 1intravitreal injectionjuvenile diabetesjuvenile diabetes mellitusketosis prone diabetesketosis resistant diabetesmaturity onset diabetesmiRNAmigrationmodel of animalmonocytenecrocytosisneuron toxicityneuronal toxicityneuropathicneurotoxicityneutrophilnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpathophysiologypharmaceutical interventionpharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsplasmalemmapreservationpreventpreventingprogramsproliferative diabetic retinopathyrepairrepair functionrepairedreparative functionresponseretina blood vessel structureretinal vascular networkretinal vascular structureretinal vasculaturerhuMabVEGFsiRNAsocial rolesubcutaneoussubdermalsystemic inflammationsystemic inflammatory responsetherapeutic evaluationtherapeutic testingtype 2 DMtype I diabetestype II DMtype one diabetestype two diabetesvascular
Description preview
Evidence from large-scale clinical trials demonstrate strong association between lipid abnormalities and
progression of diabetic retinopathy (DR), however the mechanism of dyslipidemia induced damage and the
action of lipid targeting drugs in the retina are incompletely understood. Acid sphingomyelinase (ASM) is
upregulated in diabetic retina and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click